FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to pharmacogenetics. Disclosed is a method for improving the safety of drug administration in treating patients with alcohol withdrawal syndrome based on genotyping results on polymorphic markers of CYP3A5*3, CYP2C9*3 and ABCB1 3435C>T genes. If observing carrier of polymorphic allele CYP2C9*3 (AC or CC genotype) or ABCB1 3435 T (genotype CT or TT) or in absence of polymorphous homozygous genotype CYP3A5*3 (GA or AA genotype), reducing dosage of phenazepam by 50 % of average recommended by instruction or replacing the drug with a benzodiazepine tranquilizer not exposed to hepatic metabolism – lorazepam or oxazepam.
EFFECT: invention provides higher safety of pharmacotherapy and reduced risk of unfavorable adverse reactions.
1 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR CHOOSING STARTING ANALGESIC DRUGS IN THE POSTOPERATIVE PERIOD AFTER CARDIAC SURGERY | 2021 |
|
RU2774227C1 |
| METHOD FOR CHOOSING THE STARTING SCHEME OF POSTOPERATIVE ANESTHESIA IN PATIENTS AFTER VIDEOLAPAROSCOPIC CHOLECYSTECTOMY | 2021 |
|
RU2779003C1 |
| METHOD OF ESTIMATING THE EFFICACY OF FLUVOXAMINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2722834C1 |
| METHOD OF SELECTING TREATMENT TACTICS FOR PATIENTS WITH ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL DISORDERS | 2022 |
|
RU2810798C1 |
| METHOD FOR PREDICTION OF EVALUATION OF EFFICACY OF DAPOXETINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2717245C1 |
| METHOD OF ESTIMATING THE EFFECTIVENESS OF MIRTAZAPINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2734347C1 |
| METHOD FOR SELECTING THERAPEUTIC APPROACH IN PATIENTS WITH SCHIZOPHRENIA | 2022 |
|
RU2821045C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF HALOPERIDOL THERAPY FOR THE TREATMENT OF DISORDERS ACCOMPANIED BY THE DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2017 |
|
RU2643944C1 |
| METHOD FOR PREDICTING THE EFFICACY OF LEVOMEPROMAZINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPING PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695657C1 |
| METHOD FOR PREDICTION OF CHLORPROMAZINE THERAPY EFFECTIVENESS EVALUATION FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695658C1 |
